AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06120361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma neurofilament light (NfL)
Description: The cut off will be predefined. The samples will be analysed prospectively every two weeks.
Study NCT06120361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma Ab42/Ab40
Description: The cut off will be predefined. The samples will be analysed prospectively every two weeks.
Study NCT06120361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI and CT of the brain
Description: Structural brain imaging
Study NCT06120361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Different cognitive tests
Description: Both standard paper-and-pen tests as well as digital cognitive tests will be evaluated.
Study NCT02354170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Study NCT02354170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03911544 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIS monitor
Description: Participants allocated to the intervention group will receive TIVA anesthesia adjusted by the BIS monitoring in addition to clinical signs of poor anesthesia.
Study NCT00649415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: piroxicam
Description: piroxicam 40 mg capsule QD for up to the first 3 days of the menstrual cycle
Study NCT00649415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg capsule twice a day (BID), taken as required, on the first day of treatment in the menstrual cycle followed by oral valdecoxib 40 mg once a day (QD) for up to the first 3 days of the menstural cycle
Study NCT01866722 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will get a brief (\<5 min) telephone counseling session about quitting. After that, printed materials with resources to help quitting will be mailed to the participants.
Study NCT01866722 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduction
Description: Participants will have 3 telephone counseling sessions that focus on ways to reduce tobacco cigarette smoking. After the final session printed materials with resources to help quitting will be mailed to the participants.
Study NCT01866722 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 5Rs
Description: Participants will have 3 telephone counseling sessions that focus on the 5Rs for quitting tobacco cigarette smoking (Relevance, Risks, Rewards, Roadblocks, Repeat). After the final session printed materials with resources to help quitting will be mailed to the participants.
Study NCT03015883 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
Study NCT04232670 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: EUS + SHAM
Description: Endoscopic Ultrasound
Study NCT04232670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS + Pancreatic Endotherapy
Description: Pancreatic endotherapy may include any or all of the following maneuvers: pancreatic endoscopic sphincterotomy, stricture dilation using a bougie or hydrostatic balloon catheter, pancreatic stone extraction with or without mechanical or electrohydraulic lithotripsy, extracorporeal shock wave lithotripsy, and stent placement.
Study NCT01321073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model 10642 Implantable Intravascular Catheter
Description: This clinical study consists of the Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System (Model 8637) to deliver Remodulin Injection. This study will focus on the safety of delivery of Remodulin Injection in the treatment of patients with PAH who meet the approved Remodulin Injection indication, using the approved formulation, and approved intravenous route of administration.
Study NCT01551537 — intervention group
Intervention type: OTHER
Intervention: Cervarix data collection
Description: Safety monitoring: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact.
Study NCT01551537 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: All adverse events will be recorded by diary card, follow-up visit or telephone contact.
Study NCT03087162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 60 mg once daily
Description: Once daily dose dexlansoprazole(Dexlansoprazole(60) OD) in experimental arm and Twice daily dose dexlansoprazole(Dexlansoprazole(60) 1 BID) in active arm
Study NCT03087162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexlansoprazole 60 mg once daily
Description: Once daily dose dexlansoprazole(Dexlansoprazole(60) OD) in experimental arm and Twice daily dose dexlansoprazole(Dexlansoprazole(60) 1 BID) in active arm
Study NCT04392570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fasting
Description: blood samplings will be taken 08:00 am and again 2 hours before breaking the fast
Study NCT04409769 — intervention group
Intervention type: OTHER
Intervention: Description of use of ceftaroline and ceftobiprole
Description: Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. Description of condition of use of thoses antibiotics in PJI and BJI
Study NCT03937869 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Secnidazole
Description: One dose
Study NCT05994560 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: With temporary occlusion
Description: at the time of surgery the randomization table was consulted and if it was in the occlusion arm was performed
Study NCT05994560 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: With temporary occlusion
Description: at the time of surgery the randomization table was consulted and if it was in the occlusion arm was performed
Study NCT04586361 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RegenLab PRP
Description: PRP preparations also improved functional outcome scores compared to hyaluronic acid and placebo in patients affected by knee osteoarthritis (OA). Based on previous studys, we can conclude that the PRP treatment is a safe and efficacious procedure which can provide functional benefit.
Study NCT04586361 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: hyaluronic acid
Description: Few studies investigated the effects of HA+PRP combined treatment for knee osteoarthritis (OA). Numerous studies demonstrated the efficacy of HA injection therapy in knee OA for a clinical point of view, reducing the pain and improving the quality of life.
Study NCT04586361 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: In this study, we compare introperative PRP/PRP+HA/normal saline in ACL reconstruction patient.
Study NCT00517803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Yogurt B: with various micronutrients
Description: 175g probiotic yogurt / day 25% RDA for each nutrient
Study NCT00517803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Yogurt A: Kaiser micronutrients
Description: 175g probiotic yogurt/ day 25% RDA for each nutrient
Study NCT03909139 — intervention group
Intervention type: BIOLOGICAL
Intervention: BMAC
Description: A bone marrow biopsy needle will be inserted through an arthroscopy portal and directed to the acetabuloplasty site. Bone marrow is aspirated then centrifuged. From the centrifuged sample, the buffy coat layer (layer of cells, found between the red blood cells and the plasma layers) is removed. The buffy coat layer contains mesenchymal stromal cells. This is called BMAC or Bone Marrow Aspirate Concentrate. The BMAC will be injected into the intra-articular space.
Study NCT00517803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt C: with basic micronutrients
Description: 175g yogurt/ day 25% RDA for each nutrient
Study NCT00517803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic Yogurt D: Placebo -- no added micronutrients
Description: 175g/day probiotic yogurt
Study NCT01586208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valproic acid (VPA)
Description: Best dosage at the initial bolus of VPA in patient with satatus epilepticus refractarius (after benzodiazepine + phenytoin treatment)
Study NCT03673514 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: Two fellowship-trained surgeons in two separate hospitals performed all procedures. Both surgeons had previously performed over 100 cases with each approach, before initiating this study
Study NCT00834158 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: 1 time
Study NCT00834158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: 1 time
Study NCT00834158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVE
Description: 1 time
Study NCT02092701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Study NCT03355092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vBloc Therapy
Description: The vBloc device will be placed using a laparoscopic procedure. The participants will be followed according to standard clinical practice and vBloc therapy protocol under the supervision of study surgeons. . Pre-operative testing will be conducted per surgeon's evaluation. Participants will receive weight management education according to the vBloc Therapy protocol.
Study NCT01992939 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specialized pulse oximetry probe with external heat pack
Description: Pulse oximetry will be obtained using the specialized pulse oximetry probe with external heat pack for 45 minutes.
Study NCT01992939 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Pulse Oximetry Probe
Description: Pulse oximetry will be obtained using a standard of care pulse oximetry probe for 45 minutes.
Study NCT02976064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PreHabilitation
Description: 1. Case identification: Candidates fulfilling the inclusion criteria will be identified by the anesthesiologist.~2. Case evaluation: Candidates will be assessed to identify the overall needs and perform a baseline evaluation.~3. Personalized Work plan definition: Personalization of the plan involves a calendar and planning of face to face visits and remote contacts; intensity of the supervised exercise training program; threshold of steps per day; nutritional intervention; psychological intervention; and integration of the intervention into the overall work plan.~4. Work plan execution \& 5-Follow-up+event handling: Involve the follow-up tasks, including non-scheduled interactions through the personal health folder (PHF)~6-Discharge: Patient will be discharged from prehabilitation and moved to rehabilitation.
Study NCT02976064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation in chronic stable patients in primary care
Description: 1. Case identification: Candidates fulfilling the inclusion criteria will be identified by the general practitioner.~2. Case evaluation: The primary care team will characterize the candidates, covering: i) patient requirements defining the work plan; ii) aerobic capacity and physical activity; iii) identification of factors modulating adherence.~3. Personalized work plan definition: The community-based intervention will include reassessment of the patient's work plan aiming at optimization of both pharmacological and non-pharmacological therapies. Consist of a motivational interview and a physical activity (PA) intervention (6-month duration) based on supervised endurance training, promotion of PA and empowerment for self-management using the PHF.~4. Work plan execution \& 5-Follow-up+event handling: The ICT-support will facilitate the program follow up.~6-Discharge: The patient will be discharged or moved to the PA service addressed to citizens at risk \& patients with mild disease.
Study NCT02976064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation in mild chronic patients and citizens at risk
Description: 1. Case identification: Candidates fulfilling the inclusion criteria will be identified by the GP.~2. Case evaluation: i) patient requirements defining the work plan; ii) aerobic capacity and PA; iii) identification of factors modulating adherence.~3. Personalized work plan definition: i) motivational interview; ii) training for the use of the PHF for self-management; and iii) assign one case manager for off-line remote surveillance. The following optional modules are envisaged: i) basic service (above); ii) endurance training programs; iii) community physical activity group sessions; and/or, iv) upgraded PA program including sensors and close off-line supervision.~4. Work plan execution \& 5-Follow-up+event handling: The ICT-support will facilitate the program follow up.~6-Discharge: The basic version of the promotion of PA program is conceived for a timeless duration. However, the different modules included in the service portfolio will have specific agendas and associated costs.
Study NCT01292837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: The initial dose is 20 mg/kg/day or 1000 mg/day, divided into two equal dose for the first two weeks, followed by 40 mg/kg/day or 2000 mg/day for two weeks. After reaching 60 mg/kg/day or 3000 mg/day, treatment will continue for 20 weeks.
Study NCT03259113 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Insertable cardiac monitor
Description: Insertable cardiac monitor (SJM Confirm Rx) subcutaneously.
Study NCT02922491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: daily intake of vitamin E
Study NCT03696186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luminal type-1
Description: Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
Study NCT03696186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luminal type-2
Description: Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+Prednisone (5 mg, twice daily)
Study NCT03696186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuroendocrine type-1
Description: Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
Study NCT03696186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuroendocrine type-2
Description: Goserelin (3.75mg, once every 4 weeks)+Carboplatin (area under the curve 5 on day 1 every 3 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
Study NCT03696186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atypical type-1
Description: Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
Study NCT03696186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atypical type-2
Description: Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+ targeted therapy according to next Generation Sequencing (NGS)+ Prednisone (5 mg, twice daily), or Goserelin (3.75mg, once every 4 weeks)+Abiraterone+ Prednisone (5 mg, twice daily) if no druggable gene mutation detected.
Study NCT06184087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational/Instructional
Description: ICAP constructive-interactive engagement mode
Study NCT02922491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: starch
Description: daily intake of starch (control)
Study NCT03437668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WSE
Description: WSE tablets
Study NCT03437668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet
Study NCT04087096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab will be administered at postoperative months 1, 7, and 13
Study NCT00295503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/kg IV every 3 weeks
Study NCT00295503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2 IV every 3 weeks
Study NCT04087096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered at postoperative months 1, 7, and 13
Study NCT02957565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline Questionnaires
Description: Participant completes 5 questionnaires during an already-scheduled office visit. Questionnaires ask about symptoms, physical and emotional health, and trust in the medical profession. These questionnaires should take about 17 minutes to complete.
Study NCT04087096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic Acid 5mg will be administered intravenously at postoperative month 19
Study NCT04087096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zoledronic Acid
Description: Zoledronic Acid 5mg will be administered intravenously at postoperative month 19
Study NCT03356483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin (0.25mg/kg)
Description: Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic.
Study NCT00295503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m2 every 3 weeks
Study NCT03356483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Niacin (250mg)
Description: A medication used to treat high cholesterol, triglyceride levels, and niacin deficiency.
Study NCT00614744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
Study NCT00614744 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normothermic Control
Description: Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
Study NCT03424239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: 5mg zoledronic acid
Study NCT03424239 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium citrate + vitamin D
Description: Chewable 500mg calcium citrate with 500 International Units (IU) Vitamin D3
Study NCT03424239 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 1000IU Vitamin D3 gummy
Study NCT05871242 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus crispatus M247
Description: Patient who have received probiotic Lactobacillus crispatus M247
Study NCT00770211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin) (20 Units)
Description: The treatment will be administered only once at day 0 at five injection sites in the glabellar area. The total dose of 20 Units IncobotulinumtoxinA (Xeomin) is reconstituted in a total injection volume of 0.5 mL that is to be injected to the five sites in equal aliquots of 0.1 mL.
Study NCT00770211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
Study NCT03031704 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic mucosectomy
Description: Performing adenoma resection through standardized endoscopic mucosectomy of duodenal adenoma.
Study NCT02509403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils infused Perineal Hygiene wipe
Description: Each participant will be asked to complete a treatment period of one month's duration. At the start of the study, the participants will be asked to fill-out a baseline questionnaire and will be given a month's supply of the perineal hygiene towel with instructions about its use. At day 15, 30 and 45 follow-ups will be conducted.
Study NCT03109106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCT Arm
Description: PCT-guided antibiotic therapy per study protocol
Study NCT02957565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videos
Description: Participant watches 2 short videos that show actors playing doctor and patient roles, discussing different cancer-related symptom treatment options. Each video is about 4 minutes long and discusses the same content, but setting of each video is different.
Study NCT01248221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C]-Spirulina platensis and 99mTc sulfur colloid
Description: The subject will consume the test meal containing 13C-Spirulina and 99mTc sulfur colloid in no more than 10 minutes. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
Study NCT01822821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: Patients will receive up to four doses of IV Acetaminophen (1000mg)every six hours after surgery along with standard PCA (patient controlled) opioids.
Study NCT01822821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive up to four doses placebo every six hours after surgery along with standard PCA (patient controlled) opioids.